Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Topoisomerase II enzymes play an essential role in human DNA metabolism. They are also recognized as primary targets of a number of anti-cancer drugs used in the treatment of breast cancer, which remains a leading cause of cancer-related death in women. While topoisomerase inhibitors have produced significant response rates in this disease, their use has been limited both by toxicity and by the development of resistance. In this article we review the extensive work which has not only increased our understanding of the biochemistry and molecular biology of type II topoisomerases but also enabled more rational drug design. Such knowledge should translate into increased clinical efficacy in the treatment of breast cancer and other malignancies.

Original publication

DOI

10.1097/00001813-199504000-00002

Type

Journal article

Journal

Anticancer Drugs

Publication Date

04/1995

Volume

6

Pages

195 - 211

Keywords

Antineoplastic Agents, Breast Neoplasms, DNA Topoisomerases, Type II, Drug Resistance, Female, Humans, Topoisomerase II Inhibitors